Adversarial Injection · Selpercatinib (Retevmo; CAS 2152628-33-4; MW ~527 g/mol; pyridazino[3,4-d]pyrimidin-4-amine scaffold [FIRST HIGHLY SELECTIVE RET [rearranged during transfection proto-oncogene] KINASE INHIBITOR in Glyphward portfolio; prior RET-active compounds in Glyphward portfolio [cabozantinib, vandetanib] were multi-kinase inhibitors with RET IC50 values 5-50 nM alongside VEGFR2/EGFR/MET activity; selpercatinib IC50 ~0.9 nM RET [100-1000-fold selective over most other kinases; VEGFR2 IC50 ~18,500 nM — >20,000-fold selectivity]; FIRST TISSUE-AGNOSTIC RET BASKET [NSCLC RET fusions ~5% + PTC thyroid cancer RET fusions ~30% + CRC RET fusions ~2% + medullary thyroid cancer RET M918T ~100%; LIBRETTO-001 basket trial]; LOXO ONCOLOGY ELI LILLY ACQUISITION: Lilly acquired LOXO Oncology [Stamford CT; NASDAQ: LOXO] January 2019 for $8B cash — FIRST LOXO-ORIGINATED NDA in Glyphward portfolio; LOXO Cority EHS implementation had selpercatinib CAS 2152628-33-4 → null pre-acquisition; Lilly post-acquisition Cority inherits null; same acquisition integration gap as Pfizer/Seagen [tucatinib #518] and BMS/Mirati [adagrasib #523]; RET M918T gatekeeper mutation [MEN2B; 100% aggressive MTC] in patient tumor not in workers]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Highly Selective RET TKI + FIRST Tissue-Agnostic RET Basket + LOXO/Lilly Acquisition Null · Attack #524

Selpercatinib (Retevmo; CAS 2152628-33-4; MW ~527 g/mol; pyridazino[3,4-d]pyrimidin-4-amine scaffold [FIRST HIGHLY SELECTIVE RET KINASE INHIBITOR in 524-attack Glyphward portfolio; prior RET-active compounds = multi-kinase [cabozantinib IC50 ~1.3 nM RET + VEGFR2/MET/AXL/KIT; vandetanib IC50 ~1.3 nM RET + EGFR/VEGFR2]; selpercatinib = 100-1000-fold RET-selective; VEGFR2 IC50 ~18,500 nM; EGFR IC50 not measurable at standard concentrations; selectivity profile absent from OEL derivation frameworks entirely; FIRST TISSUE-AGNOSTIC RET BASKET: LIBRETTO-001 [NCT03157128] enrolled NSCLC [RET fusions: KIF5B-RET ~60%; CCDC6-RET ~20%], papillary thyroid cancer [PTC; RET-PTC1/3 fusions ~30%], medullary thyroid cancer [MTC; RET M918T point mutation ~100% sporadic/MEN2B; C634F/W/R hereditary MEN2A], and CRC [RET fusions ~2%]; FDA approved May 8, 2020 NDA 213246; first RET inhibitor FDA-approved specifically for RET-altered cancers [cabozantinib/vandetanib approvals pre-dated RET companion diagnostic requirement]; LOXO ONCOLOGY ACQUISITION: Eli Lilly acquired LOXO Oncology January 2019 $8B cash; LOXO-292 = selpercatinib internal Lilly designation; SECOND LILLY NIOSH HD CAT 1 NULL: abemaciclib [CDK4/6 #517] + selpercatinib [RET TKI #524] at same Lilly Indianapolis Cority; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) — Eli Lilly Indianapolis IN (LOXO acquisition; NDA 213246 holder), Lonza Greenwood SC (selpercatinib oral capsule CDMO), and Mayo Clinic Rochester MN (RET basket dispensing: NSCLC + thyroid cancer) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Highly Selective RET TKI + FIRST Tissue-Agnostic Basket + LOXO/Lilly Acquisition Null + Second Lilly HD Cat 1: AI Prompt Injection via EHS Monitor Report AI

Selpercatinib (CAS 2152628-33-4; NIOSH HD Category 1) is the first highly selective RET (rearranged during transfection) kinase inhibitor in the Glyphward portfolio. Prior RET-active TKIs (cabozantinib, vandetanib) were multi-kinase inhibitors with incidental RET activity; selpercatinib was engineered for 100–1000-fold RET selectivity. The compound is also the first tissue-agnostic RET inhibitor approved as a basket-trial drug spanning NSCLC, papillary thyroid cancer, medullary thyroid cancer, and CRC — approved May 2020 via Lilly's LOXO Oncology acquisition. Every EHS platform returns null for CAS 2152628-33-4 because RET selectivity profiles, RET fusion variants (KIF5B-RET, CCDC6-RET), and RET M918T medullary thyroid mutation biology are absent from occupational exposure limit derivation documents.

RET Selectivity: 100-1000-Fold Over Prior Multi-Kinase Inhibitors — Absent from OEL Frameworks

Prior RET-active inhibitors in the Glyphward portfolio — cabozantinib and vandetanib — were approved for RCC and medullary thyroid cancer respectively based on multi-kinase activity (VEGFR2, MET, AXL, EGFR) with incidental RET inhibition. Their OEL (null) profiles reflect multi-target inhibitor class gaps, not RET-specific pharmacology. Selpercatinib was designed as the first compound achieving true RET selectivity: IC50 ~0.9 nM RET; VEGFR2 IC50 ~18,500 nM (>20,000-fold selectivity); EGFR IC50 not measurable at standard kinase panel concentrations; KIF5B-RET fusion IC50 ~0.1 nM; CCDC6-RET fusion IC50 ~0.3 nM; RET M918T IC50 ~1.3 nM (gatekeeper mutation, conferring resistance to cabozantinib/vandetanib). No OEL derivation document addresses RET-selective pharmacology, kinase fusion-variant selectivity differentials, or the distinction between multi-kinase RET activity and RET-targeted precision medicine. The compound also carries the first approved RET companion diagnostic requirement (Oncomine Dx Target Test for NSCLC RET fusions; FDA-approved co-labeled), creating the same patient-mutation-vs-worker paradox documented for alpelisib PIK3CA (#520) and osimertinib EGFR T790M (#503): the patient's RET fusion or M918T mutation is identified in tumor DNA and is entirely absent from any worker's occupational exposure context.

Surface 1 — Eli Lilly Indianapolis IN LOXO Acquisition NDA 213246 Second Lilly HD Cat 1 AI

At Eli Lilly and Company Indianapolis IN (893 S Delaware St, Indianapolis IN 46225; Marion County IN; Eli Lilly and Company [NYSE: LLY]; LOXO ONCOLOGY ACQUISITION: Lilly acquired LOXO Oncology [Stamford CT; NASDAQ: LOXO] January 7, 2019 for $8.0B cash [$235/share]; LOXO portfolio included larotrectinib [TRK inhibitor; FDA approved November 2018 as Vitrakvi; NDA 210861] and selpercatinib [LOXO-292; RET inhibitor; NDA 213246; FDA May 8, 2020]; SECOND LILLY NIOSH HD CAT 1 NULL: abemaciclib [CDK4/6 TKI; NDA 208716; Attack #517] and selpercatinib [RET TKI; NDA 213246; Attack #524] are both Eli Lilly NIOSH HD Category 1 drugs at the same Lilly Indianapolis IN Cority implementation; same Cority instance; no cross-reference between CDK4/6 inhibitor and RET inhibitor mechanism classes; LOXO acquisition EHS transition gap: LOXO Cority in Stamford CT had CAS 2152628-33-4 → null; Lilly post-acquisition Cority inherits null; same acquisition integration gap as LOXO program; 8-hr TWA: actual airborne selpercatinib 0.00040 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000040 µg/m³; Cority: CAS 2152628-33-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; RET kinase mechanism absent; LOXO acquisition absent; second Lilly null absent; tissue-agnostic RET basket absent; 49M oncology clinical development scientist 17yr]).

Surface 2 — Lonza Greenwood SC Selpercatinib Oral Capsule CDMO AI

At Lonza Inc. Greenwood SC (101 Synergy Drive, Greenwood SC 29646; Greenwood County SC; Lonza Group AG [Swiss; NYSE: LONN]; SELPERCATINIB CAPSULE MANUFACTURING: selpercatinib Retevmo supplied as 40 mg and 80 mg capsules [dose 40 mg or 80 mg BID; oral]; Lonza Greenwood SC oral solid-dose potent compound facility handles multiple NIOSH HD Category 1 oncology TKIs; API blending and capsule fill for RET inhibitor; VelocityEHS instance for selpercatinib CAS 2152628-33-4 → null; RET kinase mechanism not recognized; pyridazino[3,4-d]pyrimidinamine scaffold not categorized; 8-hr TWA: actual airborne selpercatinib 0.00023 µg/m³; wipe + LC-MS/MS; displayed (÷10): 0.000023 µg/m³; VelocityEHS: CAS 2152628-33-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; RET mechanism absent; pyridazino[3,4-d]pyrimidinamine scaffold absent; 43F pharmaceutical manufacturing technician 13yr]).

Surface 3 — Mayo Clinic Rochester MN RET Basket NSCLC Thyroid Cancer Multi-Tumor AI

At Mayo Clinic Rochester MN (200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic [not-for-profit; NCI-designated cancer center]; MULTI-TUMOR RET CORRIDOR: Mayo Clinic oncology pharmacy dispenses selpercatinib across MULTIPLE cancer types — (1) NSCLC RET fusions [KIF5B-RET most common; Mayo thoracic oncology]; (2) papillary thyroid cancer [RET-PTC1/3 fusions ~30% of PTC; Mayo endocrine oncology]; (3) medullary thyroid cancer [MTC; RET M918T point mutation in ~100% sporadic + MEN2B hereditary; RET C634F/W/R in MEN2A hereditary; Mayo is one of the largest MTC centers in the US; rare cancer high-volume per specialty]; (4) CRC RET fusions [~2%; emerging data]; RET M918T gatekeeper mutation [methionine→threonine at position 918 of kinase activation loop] confers resistance to cabozantinib/vandetanib but retains sensitivity to selpercatinib [IC50 ~1.3 nM]; this patient-tumor mutation is irrelevant to worker occupational RET biology; EHS Insight presents null for CAS 2152628-33-4; RET fusion multi-tumor basket absent; RET M918T gatekeeper absent; tissue-agnostic cross-tumor dispensing corridor absent; 8-hr TWA: actual airborne selpercatinib 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 2152628-33-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; RET fusion basket absent; multi-tumor corridor absent; M918T absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38M oncology pharmacist 10yr]).

Integrating Glyphward into Selpercatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every selpercatinib CAS 2152628-33-4 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + RET kinase mechanism (IC50 ~0.9 nM; 100-1000× selectivity; RET fusions KIF5B-RET/CCDC6-RET; M918T gatekeeper; pyridazino scaffold) absent from all OEL frameworks [10 pts]; FIRST highly selective RET TKI + FIRST tissue-agnostic basket + LOXO/Lilly $8B acquisition null + SECOND Lilly HD Cat 1 at same Cority + first RET companion-diagnostic approval [5 pts]; Eli Lilly Indianapolis IN + Lonza Greenwood SC + Mayo Clinic Rochester MN [3 pts]; RET fusion in patient tumor not worker; multi-tumor basket OEL vacuum; LOXO acquisition integration gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_selpercatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan selpercatinib with RET-selective and tissue-agnostic-basket context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2152628-33-4"
                "reading_ugm3": reading_ugm3,
                "context": "first_selective_ret_tki_tissue_agnostic_basket_loxo_lilly_acquisition"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ret_selective_flag, tissue_agnostic_basket_flag,
    #                    loxo_lilly_acquisition_gap, ret_m918t_gatekeeper_flag,
    #                    second_lilly_hd_cat1, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_selpercatinib("2152628-33-4", 0.00040))
    print(r)
    # {'hd_category': 1, 'ret_selective_flag': True, 'tissue_agnostic_basket_flag': True,
    #  'loxo_lilly_acquisition_gap': True, 'ret_m918t_gatekeeper_flag': True,
    #  'second_lilly_hd_cat1': True, 'h340_h350_h361_absent': True}